Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA-directed RNA polymerase I subunit E (POLR1E) is a key structural and functional component of RNA polymerase I, a multi-subunit enzyme complex specialized for the transcription of ribosomal DNA (rDNA) into precursor rRNA in the nucleolus[3][1][4][5]. POLR1E, also referred to as RPA49, forms a heterodimer with RPA34 and plays a crucial role in promoting elongation and processivity of Pol I during rRNA synthesis[1][3]. As a central regulator of ribosome biogenesis, POLR1E is vital for sustaining high levels of cell growth and proliferation. Dysregulation of POLR1E or Pol I activity is implicated in several human diseases: Pol I activity is upregulated in many cancers to support increased protein synthesis demands, while mutations in Pol I subunits can lead to developmental disorders known as ribosomopathies (e.g., Treacher Collins syndrome)[3][4]. Inhibitors targeting Pol I or its transcription machinery are being explored as anti-cancer therapies[1][3].
Inhibition of ribosomal RNA synthesis, leading to nucleolar stress and apoptosis in cancer cells
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA-directed RNA polymerase I subunit E (POLR1E).